Posted in | Oncology | Protein Analysis

Therapeutic Vulnerabilities of RAS Oncoproteins

RAS GTPases are prototypical members of the RAS protein superfamily and regulate a diverse range of cytoplasmic signaling networks. Commonly identified as oncogenes, mutations in RAS genes result in overactivation of pathways controlling cell differentiation and growth, oncogenesis and cancer, making them a key therapeutic target.

Webinar Topics

  • Molecular biology of RAS
  • RAS as a therapeutic target
  • Identifying therapeutic vulnerabilities in RAS
  • Therapy prospects for the future

About the Presenters

Adrienne Cox is Professor in the Department of Radiation Oncology, University of North Carolina at Chapel Hill, NC, USA. Her research investigates molecular mechanisms within cancer biology, particularly the protein function of Ras family oncogenes, and how these proteins control conversion of extracellular signals to intracellular responses.

The webinar is moderated by Judy O’Rourke, Labroots.

Other Webinars from Tocris Bioscience

Life Science Webinars by Subject Matter

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.